Metabolic stability assessment of new PARP inhibitor talazoparib using validated LC-MS/MS methodology: In silico metabolic vulnerability and toxicity studies - Attwa, M W; Kadi, A A; Abdelhameed, A S; Alhazmi, H A (Drug Des Devel Ther, 2020)